Noticias

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular […]

The average American household spends about $519 a month on groceries, based on the latest BLS Consumer Expenditure Survey figure of $6,224 a year, and grocery prices are still rising: food-at-home prices were up 1.9% year over year as of March 2026. Add about $280 for utilities and roughly $100 for phone and internet, plus ... A $185,000 Portfolio That Covers Your Groceries, Utilities, and Phone Bill Every Month

Merck (NYSE:MRK) reported progress on its investigational oral PCSK9 inhibitor, enlicitide decanoate, including a biocatalytic large-scale manufacturing method. The company highlighted this new synthesis platform as a potential template for more sustainable macrocyclic peptide production. Separately, Merck faces an upcoming high profile trial concerning the safety of Gardasil, its widely used HPV vaccine. For investors watching NYSE:MRK, these updates sit alongside a stock that is priced at...

The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.

Merck heads toward a July 27 Gardasil trial while defending the HPV vaccine's safety record.

They can weather many storms.

Moby summary of Codexis, Inc.'s Q1 2026 earnings call

An $83,400 annual paycheck sits comfortably above the U.S. median household income of roughly $80,610. Replacing that income with a portfolio, no employer required, is the question this article answers. The basic formula is income target divided by yield equals capital required. The more important issue is what changes across three yield tiers, and why ... A $1.5 Million Portfolio That Quietly Pays You $83,400 a Year, No Job Required

Over the last 7 days, the United States market has risen 3.2%, contributing to a 31% increase over the past year, with earnings expected to grow by 16% per annum in the coming years. In this thriving environment, identifying stocks that are trading below their estimated intrinsic value can be an effective strategy for investors looking to capitalize on potential growth opportunities.

Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million

Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both entered 2026 with fresh distributions and updated holdings. The two funds chase dividends through very different rule sets, and the gap between them is wider than the surface suggests. Quality Screen vs. Yield ... Vanguard High Dividend Yield ETF Delivers 67% Five-Year Returns Against Schwab U.S. Dividend Equity ETF’s Steadier 229% Decade Gain

Mounjaro generated $8.66 billion in sales in the first quarter.

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Merck Animal Health selects Salesforce's Agentforce Life Sciences to support unified omnichannel engagement for veterinarians and animal health providers. New integrations from eGain and Mili extend Salesforce's AI capabilities into Service Cloud and private client workflows. These customer wins and ecosystem additions highlight further adoption of Salesforce's AI platform beyond prior product announcements. For investors watching Salesforce (NYSE:CRM), the focus has shifted from product...

With an upside potential of 21.26% as of May 3, Merck & Co., Inc. (NYSE:MRK) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. […]

EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Wondering whether Merck’s current share price reflects its real value, or if the stock might be pricing in more than it should. Merck closed at US$113.15, with returns of 2.8% over 7 days, a 6.4% decline over 30 days, 6.3% year to date and 48.4% over the last year. Recent headlines around Merck have kept investors focused on how the company is being priced, with attention on its long term prospects and capital allocation decisions. This context helps explain why the stock’s recent moves have...

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of